Drugs of Abuse Testing Educational Resources

Access educational content focusing on key areas such as drug courts, automating drug testing, oral fluid testing, drug trends and much more. Here you will find on-demand webinars from key opinion leaders, presentations, resources, and videos.

How to use drug testing data to increase funding?


This webinar highlights how drug testing data lead to funding Georgia’s first Opioid Treatment Court. This narrative format will focus on how to discuss local data, where to find unique funding sources, and how to increase support locally.

View webinar ›

Is it okay to drink alcohol during pregnancy?

Watch this webinar to learn from an expert roundtable discussing alcohol abuse during pregnancy and Fetal Alcohol Spectrum Disorder (FASD). Three experts present the state of art from different perspectives, discussing epidemiology, framework of this disorder, related consequences, patient management and available diagnositc pathways. 
View webinar ›

How to solve daily challenges? 
Best practices from a modern toxicology laboratory

Watch this webinar to learn best practices from modern toxicology laboratories. Two lab experts share their experience with you. Topics covered include result interpretation in different settings (forensic, clincial and workplace drug testing), opportunities for workflow optimization and informing clinicians for better patient management. 
View webinar ›

Opioid or Opiate and Polysubstance use – the importance of cross-reactivity and pharmacology in drug testing outcomes

Watch this 2-part webinar series to learn more about opioid or opiate and polysubsatnce use, including the fundamental principles of cross-reactivity and drug pharmacology in drug testing of opiates and opioids. In addition, review the pharmokinetics, pharmodynamics and different routes of administration of opioids as well as the biotransformation pathways and mechanisms for the effects of opioids.
View webinar ›

The A, D, M and E in Alcohol that helps clarify dependence and intoxication

Watch this webinar to learn more about alchohol screening fundamentals related to EtG and EtS. This webinar covers mulitple topics, including detection windows and interpretation of results, the basic principles of pharmacology as it relates to ethanol, and the different routes of administration, biotransformation pathways and mechanisms for the effects of ethanol.
View webinar ›

The Use of Medical Marijuana and CBD in the Courts

Watch this webinar to understand the current status of medical marijuana and CBD use in treatment courts as well as probation, parole, and pretrial release and diversion/deferred sentencing. Review developing case law and applicable state and federal legislative schemes. 
View webinar ›

Legalization of Hemp: Its Impact on Testing

Watch this webinar to understand how the legalization of hemp has impacted court, roadside law enforcement, and workplace drug testing. You will learn about the legal history and status of hemp, the differences between marijuana and hemp derivatives, testing methods and developing issues when testing for hemp derivatives, and developing issues with erroneous testing results.
View webinar ›

Delta Dawn: The rise of alternatives to Delta 9 THC

Watch this webinar now to understand the complexities and challenges of Cannabis drug screening. You’ll learn about the plethora of analogs, such as CBD, delta-9 THC and delta-8 THC, the physical effects of each, lack of product standardization and how it complicates drug screening.
View webinar ›

Curbing the Opioid Crisis: The Role of the Clinical Laboratory for Pain Management

Learn about the history and depth of the Opioid Crisis and the importance of the clinical laboratory in the patient continuum. You'll also learn about the important advantages of using urine drug-screening technology to eliminate cross-reactivity with other drugs, the benefits of oral fluid testing, and the role of LC-MS for confirmation testing of urine and oral fluids.
View webinar ›

Strategies to Optimize Drug Testing: What's In Your Panel and What Are You Missing?

Do you need help in planning your drug testing protocols? This webinar will provide several tools to help you define drug test panels and testing strategies for your laboratory as well as approaches to ensure that they remain relevant as the toxicology landscape continues to evolve.
View webinar ›

How to Serve Drug Court Participants Safely & Cost-Effectively During the COVID-19 Pandemic

Learn how to identify drug testing strategies that will address both the safety and cost-effectiveness obstacles you face during this global pandemic. You’ll also hear examples of what other drug courts have done to mitigate risk and/or reduce operating costs.
View webinar ›

Implementing Automated Drug Testing Strategies for Better Outcomes

Learn how a small drug court dropped their recidivism rates to almost zero by implementing automated drug testing. Despite the fear of automation and implementation hurdles, automated drug testing delivered dramatic results.
View webinar ›

Kratom abuse is on the rise
The next chapter in the Opioid Crisis!

Drug testing facilities should be screening for Kratom, an opioid with potential for addiction and abuse. It is crucial to understand the physiological and psychological effects of Kratom, and how it is being used as an alternative to other opioids.
View webinar ›

Poppy Seed Pastries

The Opioid Crisis: What you need to know!

Speaker Pat Pizzo discusses the opioid crisis, commonly abused drugs, current trends, the difference between prescription and street drugs, and available tests for opioid detection.
View webinar ›

Drugs of Abuse - Spice

Abuse of Synthetic Cannabinoids - "Spice"

Synthetic cannabinoids are the largest and fastest growing group of new psychoactive substances on the market. But, what are synthetic cannabinoids and why do you need to know about them?
View webinar › 

john-douglas-build-drug-court-lab

How to build your drug court lab

What does it take to set up a successful on-site Drug Court testing laboratory? Learn the benefits, considerations, and challenges during this webinar.
View webinar › 

pat-pizzo-truth-behind-drug-screening-270x195

The truth behind drug screening

Learn about the pros and cons of various drug screening methods and sample types for drug court testing programs from industry-expert Pat Pizzo.
View webinar ›

pat-pizzo-nadcp-2015-270x195

Seminar: Drug testing for common drugs of abuse

Industry expert Pat Pizzo discusses drug test results you receive from the laboratory, new drugs, synthetic cannabinoids, synthetic stimulants and naturally-occurring plant materials.
Request presentation ›

judge-brian-mackenzie-nadcp-2016-270x195

Seminar: Drug Court Standards of Automated Drug Testing

Judge Brian MacKenzie, ret. dispels the myths commonly associated with instrument testing cost and discusses the real value that laboratory automation brings to drug courts and their participants, such as speed and accuracy of drug test results.
Request presentation ›

Follow the Cup: Automated Drug Testing Solutions

Automated drug testing is easier than one might initially think. Watch our video to learn more about the Thermo Scientific™ Complete Automated Drugs of Abuse Testing Solution and how it can fit the needs of your drug testing program.

Learn more ›

Simplify oral fluid collection for drugs of abuse testing

Simplify the collection of oral samples for routine drug testing with our Therrmo Scientific™ Oral-Eze™ Oral Fluid collection device. It provides all the advantages of previous collection systems with the added benefit of our indicator window technology—taking the guesswork out of sample collection.

Learn more ›

Automated Drug Testing

automated-drugs-of-abuse-testing-indiko-analyzer

Learn more ›

Urine Drugs of Abuse Testing Assays

drugs-of-abuse-testing-overview

Learn more ›

Oral Fluid Drugs of Abuse Testing

OFT_Head_270x195

Learn more ›

Technical Resources

SmartNote-Fanout_270x195
Thermo Scientific High Performing Drugs of Abuse Assays

Request whitepaper

Thermo Scientific High Performing Drugs of Abuse Assays

Download this review of over 30 peer-reviewed articles that support the use of the Thermo Scientific Immunoassays as a reliable and accurate method for drugs of abuse screening. The Thermo Scientific comprehensive menu of drugs of abuse tests utilizes well-established DRI™ and CEDIA™ technologies, which have proven assay performance, are easy to use, and are valued for accuracy, specificity, and reproducibility.

Request application note

Global Drug Abuse Trends: A summary of Journal publications on drugs of abuse testing immunoassays

This technical note describes the global public health crisis stemming from illicit drug use, delineates global drug trends by drug type and geographies and describes DRI and CEDIA immunoassay technologies for screening drugs of abuse. It presents a review of 16 key journal publications highlighting the performance and cross-reactivity of Thermo Scientific immunoassays on different analyzers.

Customer Stories

drug-court-case-study-270x195

Amphetamine/Ecstasy

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  3. Petrie, Lynch, Ekins, Chang, Goetz, Wu, Krasowski: Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays, Clinical Toxicology 2013; 51: 83-91
  4. Kaplan, Erol, Karadas: False-Positive Amphetamine/Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (CEDIA) and Ecstasy (MDMA/3,4 Methylenedioxymethamphetamine) (DRI) Test Results with Fenofibrate, Ther Drug Monit 2012; 34(5): 493-5
  5. Vidal, Skripuletz: Bupropion Interference With Immunoassays for Amphetamines and LSD, Ther Drug Monit 2007; 29(3): 373-5
  6. Nguyen, Bui, Ambrose: Response of CEDIA amphetamines assay after a single dose of bitter orange, Ther Drug Monit 2006 Apr; 28(2): 252-4

Benzodiazepine

  1. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  2. DeRienz, Holler, Manos, Jemionek, Past: Evaluation of Four Immunoassay Screening Kits for the Detection of Benzodiazepines in Urine, J Anal Toxicol 2008; 32: 433-437

Buprenorphine

  1. Berg, Schjøtt, Fossan, Riedel: Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids, Substance Abuse and Rehabilitation 2015:6 131–139
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  3. Birch, Couchman, Pietromartire, Karna, Paton, McAllister, Marsh, Flanagan: False-Positive Buprenorphine by CEDIA in Patients Prescribed Amisulpride and Sulpiride, J Anal Toxicol 2013; 37(4): 233-6
  4. Shaikh, Hull, Bishop, Griggs, Long, Nixon, Flood: Effect of Tramadol Use on Three Point-of-Care and One Instrument-Based Immunoassays for Urine Buprenorphine, J Anal Toxicol 2008; 32: 339-343
  5. Pavlic, Libiseller, Grubwieser, Rabl: Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?, Int J Legal Med 2005; 119: 378-381
  6. Böttcher, Beck: Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment, J Anal Toxicol 2005; Vol. 29: 769-776

Cocaine

  1. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499

Ethyl Glucuronide

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Arndt, Beyreiß, Schröfel, Stemmerich: Cross-reaction of propyl and butyl alcohol glucuronides with an ethyl glucuronide enzyme immunoassay, Forensic Sci Int 2014; 241: 84-86 Test Results With Fenofibrate, Ther Drug Monit 2012; 34(5): 493-5
  3. Arndt, Grüner, Schröfel, Stemmerich: Falsch-positives Ethylglucuronid-Screening nach Inhalation von Dämpfen eines propanolbasierten, ethanolfreien Handdesinfizienz, Toxichem Krimtech 2012; 79(3): 147-149
  4. Arnst, Grüner, Schröfel, Stemmerich: False-positive ethyl glucuronide immunoassay screening caused by a propyl alcohol-based hand sanitizer, Forensic Sci Int 2012; 223: 359-363
  5. Arndt, Gierten, Güssregen,Werle, Grüner: False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC-MS/MS and self medication, Forensic Sci Int 2009; 184(1-3): e27-9

Fentanyl

  1. Wang, Colby, Wu, Lynch: Cross-Reactivity of Acetylfentanyl and Risperidone With a Fentanyl Immunoassay, J Anal Toxicol 2014; 38: 672-675

Heroin Metabolite (6-Acetylmorphine)

  1. Jenkins, Lavins, Snyder: Evaluation of the Cedia® Heroin Metabolite (6-AM) Immunoassay with Urine Specimens from a Criminal Justice Drug-Testing Program, J Anal Toxicol 2005; 28: 201-204

LSD

  1. Röhrich, Zörntlein, Lotz, Becker, Kern, Ritter: False-positive LSD Testing in Urine Samples from Intensive Care Patients, J Anal Toxicol 1998; 22: 393-395
  2. Vidal, Skripuletz: Bupropion Interference With Immunoassays for Amphetamines and LSD, Ther Drug Monit 2007; 29(3): 373-5
  3. Grobosch, Lemm-Ahlers: Immunoassay Screening of Lysergic Acid Diethylamide (LSD) and its Confirmation by HPLC and Fluorescence Detection Following LSD ImmunElute Extraction, J Anal Toxicol 2002; 26: 181-186

Methadone

  1. Collins, Merritt, Bourland: Cross-Reactivity of Tapentadol Specimens with DRI Methadone Enzyme Immunoassay, J Anal Toxicol 2012; 36(8): 582-587

Methaqualone

  1. Collins, Merritt, Bourland: Cross-Reactivity of Tapentadol Specimens with DRI Methadone Enzyme Immunoassay, J Anal Toxicol 2012; 36(8): 582-587

Opiate

  1. Straseski, Stolbach, Clarke: Opiate-Positive Immunoassay Screen in a Pediatric Patient, Clinical Chemistry 2010; 56(8): 1220-1225

Oxycodone

  1. Jenkins, Poirier, Juhascik: Cross-Reactivity of Naloxone with Oxycodone Immunoassays: Implications for Individuals Taking Suboxone, Clinical Chemistry 2009; 55(7): 1434-6

Phencyclidine (PCP)

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
On-Demand Webinars

How to use drug testing data to increase funding?


This webinar highlights how drug testing data lead to funding Georgia’s first Opioid Treatment Court. This narrative format will focus on how to discuss local data, where to find unique funding sources, and how to increase support locally.

View webinar ›

Is it okay to drink alcohol during pregnancy?

Watch this webinar to learn from an expert roundtable discussing alcohol abuse during pregnancy and Fetal Alcohol Spectrum Disorder (FASD). Three experts present the state of art from different perspectives, discussing epidemiology, framework of this disorder, related consequences, patient management and available diagnositc pathways. 
View webinar ›

How to solve daily challenges? 
Best practices from a modern toxicology laboratory

Watch this webinar to learn best practices from modern toxicology laboratories. Two lab experts share their experience with you. Topics covered include result interpretation in different settings (forensic, clincial and workplace drug testing), opportunities for workflow optimization and informing clinicians for better patient management. 
View webinar ›

Opioid or Opiate and Polysubstance use – the importance of cross-reactivity and pharmacology in drug testing outcomes

Watch this 2-part webinar series to learn more about opioid or opiate and polysubsatnce use, including the fundamental principles of cross-reactivity and drug pharmacology in drug testing of opiates and opioids. In addition, review the pharmokinetics, pharmodynamics and different routes of administration of opioids as well as the biotransformation pathways and mechanisms for the effects of opioids.
View webinar ›

The A, D, M and E in Alcohol that helps clarify dependence and intoxication

Watch this webinar to learn more about alchohol screening fundamentals related to EtG and EtS. This webinar covers mulitple topics, including detection windows and interpretation of results, the basic principles of pharmacology as it relates to ethanol, and the different routes of administration, biotransformation pathways and mechanisms for the effects of ethanol.
View webinar ›

The Use of Medical Marijuana and CBD in the Courts

Watch this webinar to understand the current status of medical marijuana and CBD use in treatment courts as well as probation, parole, and pretrial release and diversion/deferred sentencing. Review developing case law and applicable state and federal legislative schemes. 
View webinar ›

Legalization of Hemp: Its Impact on Testing

Watch this webinar to understand how the legalization of hemp has impacted court, roadside law enforcement, and workplace drug testing. You will learn about the legal history and status of hemp, the differences between marijuana and hemp derivatives, testing methods and developing issues when testing for hemp derivatives, and developing issues with erroneous testing results.
View webinar ›

Delta Dawn: The rise of alternatives to Delta 9 THC

Watch this webinar now to understand the complexities and challenges of Cannabis drug screening. You’ll learn about the plethora of analogs, such as CBD, delta-9 THC and delta-8 THC, the physical effects of each, lack of product standardization and how it complicates drug screening.
View webinar ›

Curbing the Opioid Crisis: The Role of the Clinical Laboratory for Pain Management

Learn about the history and depth of the Opioid Crisis and the importance of the clinical laboratory in the patient continuum. You'll also learn about the important advantages of using urine drug-screening technology to eliminate cross-reactivity with other drugs, the benefits of oral fluid testing, and the role of LC-MS for confirmation testing of urine and oral fluids.
View webinar ›

Strategies to Optimize Drug Testing: What's In Your Panel and What Are You Missing?

Do you need help in planning your drug testing protocols? This webinar will provide several tools to help you define drug test panels and testing strategies for your laboratory as well as approaches to ensure that they remain relevant as the toxicology landscape continues to evolve.
View webinar ›

How to Serve Drug Court Participants Safely & Cost-Effectively During the COVID-19 Pandemic

Learn how to identify drug testing strategies that will address both the safety and cost-effectiveness obstacles you face during this global pandemic. You’ll also hear examples of what other drug courts have done to mitigate risk and/or reduce operating costs.
View webinar ›

Implementing Automated Drug Testing Strategies for Better Outcomes

Learn how a small drug court dropped their recidivism rates to almost zero by implementing automated drug testing. Despite the fear of automation and implementation hurdles, automated drug testing delivered dramatic results.
View webinar ›

Kratom abuse is on the rise
The next chapter in the Opioid Crisis!

Drug testing facilities should be screening for Kratom, an opioid with potential for addiction and abuse. It is crucial to understand the physiological and psychological effects of Kratom, and how it is being used as an alternative to other opioids.
View webinar ›

Poppy Seed Pastries

The Opioid Crisis: What you need to know!

Speaker Pat Pizzo discusses the opioid crisis, commonly abused drugs, current trends, the difference between prescription and street drugs, and available tests for opioid detection.
View webinar ›

Drugs of Abuse - Spice

Abuse of Synthetic Cannabinoids - "Spice"

Synthetic cannabinoids are the largest and fastest growing group of new psychoactive substances on the market. But, what are synthetic cannabinoids and why do you need to know about them?
View webinar › 

john-douglas-build-drug-court-lab

How to build your drug court lab

What does it take to set up a successful on-site Drug Court testing laboratory? Learn the benefits, considerations, and challenges during this webinar.
View webinar › 

pat-pizzo-truth-behind-drug-screening-270x195

The truth behind drug screening

Learn about the pros and cons of various drug screening methods and sample types for drug court testing programs from industry-expert Pat Pizzo.
View webinar ›

pat-pizzo-nadcp-2015-270x195

Seminar: Drug testing for common drugs of abuse

Industry expert Pat Pizzo discusses drug test results you receive from the laboratory, new drugs, synthetic cannabinoids, synthetic stimulants and naturally-occurring plant materials.
Request presentation ›

judge-brian-mackenzie-nadcp-2016-270x195

Seminar: Drug Court Standards of Automated Drug Testing

Judge Brian MacKenzie, ret. dispels the myths commonly associated with instrument testing cost and discusses the real value that laboratory automation brings to drug courts and their participants, such as speed and accuracy of drug test results.
Request presentation ›

Videos

Follow the Cup: Automated Drug Testing Solutions

Automated drug testing is easier than one might initially think. Watch our video to learn more about the Thermo Scientific™ Complete Automated Drugs of Abuse Testing Solution and how it can fit the needs of your drug testing program.

Learn more ›

Simplify oral fluid collection for drugs of abuse testing

Simplify the collection of oral samples for routine drug testing with our Therrmo Scientific™ Oral-Eze™ Oral Fluid collection device. It provides all the advantages of previous collection systems with the added benefit of our indicator window technology—taking the guesswork out of sample collection.

Learn more ›

Resources

Automated Drug Testing

automated-drugs-of-abuse-testing-indiko-analyzer

Learn more ›

Urine Drugs of Abuse Testing Assays

drugs-of-abuse-testing-overview

Learn more ›

Oral Fluid Drugs of Abuse Testing

OFT_Head_270x195

Learn more ›

Technical Resources

SmartNote-Fanout_270x195
Thermo Scientific High Performing Drugs of Abuse Assays

Request whitepaper

Thermo Scientific High Performing Drugs of Abuse Assays

Download this review of over 30 peer-reviewed articles that support the use of the Thermo Scientific Immunoassays as a reliable and accurate method for drugs of abuse screening. The Thermo Scientific comprehensive menu of drugs of abuse tests utilizes well-established DRI™ and CEDIA™ technologies, which have proven assay performance, are easy to use, and are valued for accuracy, specificity, and reproducibility.

Request application note

Global Drug Abuse Trends: A summary of Journal publications on drugs of abuse testing immunoassays

This technical note describes the global public health crisis stemming from illicit drug use, delineates global drug trends by drug type and geographies and describes DRI and CEDIA immunoassay technologies for screening drugs of abuse. It presents a review of 16 key journal publications highlighting the performance and cross-reactivity of Thermo Scientific immunoassays on different analyzers.

Customer Stories

drug-court-case-study-270x195
Publications

Amphetamine/Ecstasy

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  3. Petrie, Lynch, Ekins, Chang, Goetz, Wu, Krasowski: Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays, Clinical Toxicology 2013; 51: 83-91
  4. Kaplan, Erol, Karadas: False-Positive Amphetamine/Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (CEDIA) and Ecstasy (MDMA/3,4 Methylenedioxymethamphetamine) (DRI) Test Results with Fenofibrate, Ther Drug Monit 2012; 34(5): 493-5
  5. Vidal, Skripuletz: Bupropion Interference With Immunoassays for Amphetamines and LSD, Ther Drug Monit 2007; 29(3): 373-5
  6. Nguyen, Bui, Ambrose: Response of CEDIA amphetamines assay after a single dose of bitter orange, Ther Drug Monit 2006 Apr; 28(2): 252-4

Benzodiazepine

  1. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  2. DeRienz, Holler, Manos, Jemionek, Past: Evaluation of Four Immunoassay Screening Kits for the Detection of Benzodiazepines in Urine, J Anal Toxicol 2008; 32: 433-437

Buprenorphine

  1. Berg, Schjøtt, Fossan, Riedel: Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids, Substance Abuse and Rehabilitation 2015:6 131–139
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499
  3. Birch, Couchman, Pietromartire, Karna, Paton, McAllister, Marsh, Flanagan: False-Positive Buprenorphine by CEDIA in Patients Prescribed Amisulpride and Sulpiride, J Anal Toxicol 2013; 37(4): 233-6
  4. Shaikh, Hull, Bishop, Griggs, Long, Nixon, Flood: Effect of Tramadol Use on Three Point-of-Care and One Instrument-Based Immunoassays for Urine Buprenorphine, J Anal Toxicol 2008; 32: 339-343
  5. Pavlic, Libiseller, Grubwieser, Rabl: Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?, Int J Legal Med 2005; 119: 378-381
  6. Böttcher, Beck: Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment, J Anal Toxicol 2005; Vol. 29: 769-776

Cocaine

  1. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499

Ethyl Glucuronide

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Arndt, Beyreiß, Schröfel, Stemmerich: Cross-reaction of propyl and butyl alcohol glucuronides with an ethyl glucuronide enzyme immunoassay, Forensic Sci Int 2014; 241: 84-86 Test Results With Fenofibrate, Ther Drug Monit 2012; 34(5): 493-5
  3. Arndt, Grüner, Schröfel, Stemmerich: Falsch-positives Ethylglucuronid-Screening nach Inhalation von Dämpfen eines propanolbasierten, ethanolfreien Handdesinfizienz, Toxichem Krimtech 2012; 79(3): 147-149
  4. Arnst, Grüner, Schröfel, Stemmerich: False-positive ethyl glucuronide immunoassay screening caused by a propyl alcohol-based hand sanitizer, Forensic Sci Int 2012; 223: 359-363
  5. Arndt, Gierten, Güssregen,Werle, Grüner: False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC-MS/MS and self medication, Forensic Sci Int 2009; 184(1-3): e27-9

Fentanyl

  1. Wang, Colby, Wu, Lynch: Cross-Reactivity of Acetylfentanyl and Risperidone With a Fentanyl Immunoassay, J Anal Toxicol 2014; 38: 672-675

Heroin Metabolite (6-Acetylmorphine)

  1. Jenkins, Lavins, Snyder: Evaluation of the Cedia® Heroin Metabolite (6-AM) Immunoassay with Urine Specimens from a Criminal Justice Drug-Testing Program, J Anal Toxicol 2005; 28: 201-204

LSD

  1. Röhrich, Zörntlein, Lotz, Becker, Kern, Ritter: False-positive LSD Testing in Urine Samples from Intensive Care Patients, J Anal Toxicol 1998; 22: 393-395
  2. Vidal, Skripuletz: Bupropion Interference With Immunoassays for Amphetamines and LSD, Ther Drug Monit 2007; 29(3): 373-5
  3. Grobosch, Lemm-Ahlers: Immunoassay Screening of Lysergic Acid Diethylamide (LSD) and its Confirmation by HPLC and Fluorescence Detection Following LSD ImmunElute Extraction, J Anal Toxicol 2002; 26: 181-186

Methadone

  1. Collins, Merritt, Bourland: Cross-Reactivity of Tapentadol Specimens with DRI Methadone Enzyme Immunoassay, J Anal Toxicol 2012; 36(8): 582-587

Methaqualone

  1. Collins, Merritt, Bourland: Cross-Reactivity of Tapentadol Specimens with DRI Methadone Enzyme Immunoassay, J Anal Toxicol 2012; 36(8): 582-587

Opiate

  1. Straseski, Stolbach, Clarke: Opiate-Positive Immunoassay Screen in a Pediatric Patient, Clinical Chemistry 2010; 56(8): 1220-1225

Oxycodone

  1. Jenkins, Poirier, Juhascik: Cross-Reactivity of Naloxone with Oxycodone Immunoassays: Implications for Individuals Taking Suboxone, Clinical Chemistry 2009; 55(7): 1434-6

Phencyclidine (PCP)

  1. Regester, Chmiel, Holler, Vorce, Levine, Bosy: Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits, J Anal Toxicol 2015 Mar; 39(2): 144-51
  2. Beck, Rausberg, Al-Saffar, Villen, Karlsson, Hansson, Helander: Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse, Drug Test Analysis 2014; 6(5): 492-499